0.05Open0.05Pre Close31 Volume562 Open Interest2.50Strike Price155.00Turnover1412.27%IV62.42%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1735Delta0.4015Gamma31.40Leverage Ratio-0.2682Theta0.0000Rho5.45Eff Leverage0.0001Vega
Werewolf Therapeutics Stock Discussion
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (HOWL) presented interim Phase 1 clinical trial results for WTX-330, their tumor-activated IL-12 prodrug, at SITC's 39th Annual Meeting. The trial enrolled 25 patients with diverse solid tumors, showing favorable tolerability and encouraging efficacy. Key findings include a confirmed partial response in a ...
4 mins ago
Werewolf Therapeutics Announces Promising New Development Candidate, Wtx-921, a First-of-Its-Kind Il-10 Indukine™ Molecule for Inflammatory Diseases
📊⚡️📊
📊⚡️📊
No comment yet